Dr. Jeffrey E. Rubnitz, MD, PhD
Claim this profileSt. Jude Children's Research Hospital
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
13 reported clinical trials
25 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
t(9;11) positive
inv(16) positive
t(8;21) positive
2Acute Myeloid Leukemia
t(9;11) positive
inv(16) positive
t(8;21) positive
Affiliated Hospitals
Clinical Trials Jeffrey E. Rubnitz, MD, PhD is currently running
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML * Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secondary Objectives: \- Estimate the rates of complete remission (CR), event-free survival (EFS), and overall survival (OS) in pediatric patients who receive venetoclax-based chemotherapy
Recruiting1 award Phase 2
Talazoparib + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing the safety of using talazoparib with standard chemotherapy in cancer patients. Talazoparib works by stopping cancer cells from repairing themselves, which could make chemotherapy more effective. The study aims to find the safest dose combination and see if this approach helps patients. Talazoparib is FDA approved for certain types of breast cancer that have spread and were previously treated with chemotherapy.
Recruiting1 award Phase 119 criteria
More about Jeffrey E. Rubnitz, MD, PhD
Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jeffrey E. Rubnitz, MD, PhD has experience with
- Cytarabine
- Venetoclax
- Azacitidine
- Fludarabine
- Decitabine
- Selinexor
Breakdown of trials Jeffrey E. Rubnitz, MD, PhD has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Leukemia
Biphenotypic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey E. Rubnitz, MD, PhD specialize in?
Jeffrey E. Rubnitz, MD, PhD focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved t(9;11) positive patients, or patients who are inv(16) positive.
Is Jeffrey E. Rubnitz, MD, PhD currently recruiting for clinical trials?
Yes, Jeffrey E. Rubnitz, MD, PhD is currently recruiting for 4 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey E. Rubnitz, MD, PhD has studied deeply?
Yes, Jeffrey E. Rubnitz, MD, PhD has studied treatments such as Cytarabine, Venetoclax, Azacitidine.
What is the best way to schedule an appointment with Jeffrey E. Rubnitz, MD, PhD?
Apply for one of the trials that Jeffrey E. Rubnitz, MD, PhD is conducting.
What is the office address of Jeffrey E. Rubnitz, MD, PhD?
The office of Jeffrey E. Rubnitz, MD, PhD is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.